jeudi 20 septembre 2018

Onco Actu du 20 septembre 2018

2.6 Etiologie - Environnement

Factbox: Bayer's Monsanto faces broad U.S. glyphosate litigation [Reuters]

3.3 Prévention - Vaccins

HPV vaccine IS safe: Study finds just 0.001% of those given the life-saving jab proven to protect against several forms of cancer will experience 'serious' side effects [Daily Mail]

3.4.1 Chimioprévention - aspirine

A Run of Contrary Results [In the Pipeline]

3.7 Prévention - Alcool

Those that fail to learn from history are doomed to repeat it [BMJ]

5.10 Traitements - Essais

Denied ‘life-extending opportunities’: Black patients are being left out of clinical trials amid wave of new cancer therapies [STAT]

5.12 Immunothérapies

Liver cancer: UK’s fastest rising cause of cancer death to be tackled [Cancer Research UK]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Engineered cell therapy given initial ‘no’ for aggressive adult lymphoma on NHS in England [Cancer Research UK]

UK rejects adult Novartis CAR-T therapy, after 'yes' in kids [Reuters]

NICE encourages further discussions on Kymriah for adult lymphoma [NICE]

5.12.5 Immunothérapies - Pharma

Two Genentech vets reunite at Immune-Onc to help steer its $33M drive to the clinic [EndPoints]

5.12.8 Immunothérapies - Economie

Merck follows Opdivo’s suit, prices Keytruda in China at half its U.S. tag: report [FiercePharma]

5.2 Pharma

Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer [Janssen]

5.2.1 Pharma - Partenariats

Takeda blesses a little biotech’s engineered toxin tech for multiple myeloma, triggering a bases loaded home run [EndPoints]

5.2.3 Pharma - économie

Galera reels in $150M to test radiation side effect drug in phase 3 [FierceBiotech]

Clarus spearheads a big, $150M raise so Galera can flip the PhIII card on its new drug to treat radiation effects [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

EMA’s Committee for Medicinal Products for Human Use (CHMP) elects new chair [EMA]

Harnessing the Power of Precision Medicine – Treating Cancers with Tissue-agnostic Therapies [Cancer Research Catalyst]

5.3.4 Traitements - AMM (FDA, EMA,...)

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma [Exelixis]

5.4 Traitements - Economie

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers [PhRMA]

5.6 ESMO

ESMO 2018 Awardees announced [ESMO]

6. Lutte contre les cancers

European cancer research gets £30 million vote of confidence [Cancer Research UK]

6.10.1 Politiques (USA)

With more immigrant children in detention, HHS cuts funds for other programs — like cancer research [Yahoo News]

6.11 Patients

Siblings affected by childhood cancer: ‘I’m so proud of what he’s done and how far he’s come’ – James’s story [Cancer Research UK]

6.6 Publications

‘Journalologists’ use scientific methods to study academic publishing. Is their work improving science? [Science]

6.7.1 IA/bioinformatique

Artificial Intelligence in Medicine: 21st Century Resurgence [Informatics Professor]

6.8 Communication

'Twitter Cheerleaders': A Megaphone for Bad Science [Medscape]